Company intelligence / Profile preview
Beijing Biote Pharmaceutical Co., Ltd.
Beijing, Beijing, Chinabiotepharma.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Successfully commercialized Leuprorelin Acetate sterile lyophilized microspheres sustained release for injection, which was the first generic microsphere product marketed in China in 2009
- Therapeutic areas
- OncologyEndocrinologyWomen's Health
- Modalities
- Microsphere drug delivery systems
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Beijing Biote Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Biote Pharmaceutical Co., Ltd..